⚕ GalenOps CRO console
← SITE003 (CAN)

SITE003-0112

completed
Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE003 (CAN) (Dr. Okafor) · consented 2022-07-14
Adverse events
10
Serious AEs
0
Open data queries
0
Luna dropout signal
–

Adverse events

mild assessed 2026-08-18

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-08-12 (study day 22); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-09-01 (study day 42); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-09-19 (study day 60); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-10-10 (study day 81); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-10-19 (study day 90); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-10-30 (study day 101); relationship: N

moderate assessed 2026-08-18

Grade 2 Pneumonitis — outcome: RECOVERED/RESOLVED; onset 2022-11-03 (study day 105); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-11-06 (study day 108); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-05-28 (study day 311); relationship: N

moderate assessed 2026-08-18

Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-07-13 (study day 357); relationship: not assessed

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.